Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis

Corrigendum in: /10.3892/ijmm.2018.3617

  • Authors:
    • Mingjun Li
    • Wengang Wang
    • Li Geng
    • Yanru Qin
    • Wenjie Dong
    • Xudong Zhang
    • An Qin
    • Mingzhi Zhang
  • View Affiliations

  • Published online on: August 31, 2015     https://doi.org/10.3892/ijmm.2015.2330
  • Pages: 1335-1344
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Astragaloside IV (AS-IV) is a natural plant extract that enhances osteoblast activity, and therefore, has the potential to treat osteoclast‑related diseases. Such diseases include osteoporosis, periodontal disease, rheumatoid arthritis and aseptic prosthesis loosening. However, data associating the effects of AS‑IV on osteoclasts are limited. The aim of the present study was to assess the effect of AS‑IV on osteoclasts in vitro and in vivo. The in vitro studies demonstrated that AS‑IV exerts potent inhibitory effects on the ligand of the receptor activator of nuclear factor‑κB‑induced osteoclastogenesis and revealed the mechanism of action of AS‑IV, which inhibited osteoclastogenesis by suppression of the extracellular signal‑regulated kinase signaling pathway. The in vivo studies proved that AS‑IV attenuated titanium particle‑induced osteolysis in a mouse calvarial model. Collectively, the findings of the study suggest that AS‑IV is a potential natural agent for the treatment of osteoclast-related diseases.
View Figures
View References

Related Articles

Journal Cover

November-2015
Volume 36 Issue 5

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li M, Wang W, Geng L, Qin Y, Dong W, Zhang X, Qin A and Zhang M: Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis Corrigendum in /10.3892/ijmm.2018.3617. Int J Mol Med 36: 1335-1344, 2015
APA
Li, M., Wang, W., Geng, L., Qin, Y., Dong, W., Zhang, X. ... Zhang, M. (2015). Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis Corrigendum in /10.3892/ijmm.2018.3617. International Journal of Molecular Medicine, 36, 1335-1344. https://doi.org/10.3892/ijmm.2015.2330
MLA
Li, M., Wang, W., Geng, L., Qin, Y., Dong, W., Zhang, X., Qin, A., Zhang, M."Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis Corrigendum in /10.3892/ijmm.2018.3617". International Journal of Molecular Medicine 36.5 (2015): 1335-1344.
Chicago
Li, M., Wang, W., Geng, L., Qin, Y., Dong, W., Zhang, X., Qin, A., Zhang, M."Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis Corrigendum in /10.3892/ijmm.2018.3617". International Journal of Molecular Medicine 36, no. 5 (2015): 1335-1344. https://doi.org/10.3892/ijmm.2015.2330